CD4 and prostate cancer: Davidsson et al recently found that high numbers of stromal CD4+ Tregs were identified in patients with post‐atrophic hyperplasia and prostate cancer.10 In contrast, we found a lower Treg frequency in peripheral blood from BPH patients, but Treg infiltration increased into prostatic tissue with mild or moderate inflammation, and in severely inflamed prostates, Tregs almost disappeared.